Misys plc (FTSE: MSY.L), notes that Allscripts Healthcare Solutions, Inc. (Allscripts) (NASDAQ: MDRX) filed a definitive proxy statement with the U.S. Securities and Exchange Commission on Thursday, 21 August 2008 in respect of the proposed merger between Misys Healthcare Systems, LLC and Allscripts to form Allscripts-Misys Healthcare Solutions, Inc. (Allscripts-Misys) and related transactions, as announced by Misys on 18 March 2008. Further, Allscripts has informed its stockholders, through its proxy statement, that Allscripts intends to convene a meeting of its stockholders on 22 September 2008 to approve certain actions required to be taken by Allscripts in connection with the proposed transactions.

Misys plc (FTSE: MSY.L) announces that Misys Healthcare Systems, LLC (MHS) has received a letter sent on behalf of iMedica Corporation (“iMedica”) in respect of a contract dispute relating to the OEM Agreement (the “OEM Agreement”) entered into between MHS and iMedica announced on 28 August 2007.

London: Misys plc (FTSE: MSY.L), the global applications software and services company, announces that its registered office address has changed to:

Misys plc, One Kingdom Street, Paddington, London W2 6BL

Misys plc (FTSE: MSY.L) delivers results ahead of expectations and is now raising targets for the next phase of the turnaround.  Misys generated Group revenues¹ of £492m up 6%, bringing Group operating profit² to £81m, 37% ahead of last year. Misys is executing on its strategy and entering into the next phase of the turnaround plan, building a platform for growth.

London, (26 June, 2008) – Misys (FTSE: MSY.L), the global applications software and services company, has provided guidance to the Canadian Government’s Competition Review Panel. In its advice to the Canadian Government Misys said that, “Canada needs to use its bounty of natural resources, including its share of the Arctic, to transform into a highly educated, highly motivated and highly sought out, destination for talent and investment”.

Misys plc (FTSE: MSY.L), the global application software and services company, today, 18 June 2008, issues an unaudited trading statement for the year ended 31 May 2008.  Audited results for Misys plc will be announced in late July 2008.

London, (2 June 2008) – Misys plc (FTSE: MSY.L), the global applications software and services company, today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, in respect to the merger agreement announced on 18 March 2008 between Misys Healthcare and Allscripts (NASDAQ: MDRX) to form Allscripts-Misys Healthcare Solutions, Inc. has expired.

Misys plc, the global application software and services company, today (18 March 2008) issues the following unaudited Interim Management Statement, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

The offering information to which this gatepost gives access is exclusively intended for persons who are non-U.S. residents and who are not physically present in the United States. This information does not constitute an offer, or an invitation to purchase, securities of Misys plc, in the United States or in any other jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this offering information are requested to inform themselves about and to observe any such restrictions.

Misys plc securities cannot be offered or sold in the United States without registration under the United States Securities Act of 1933, as amended, or pursuant to an exemption from such registration. Misys plc has not registered, and does not intend to register, any of its securities under the Securities Act or to conduct a public offering of securities in the United States.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

Misys announces that it is today conditionally placing 42,857,143 new ordinary shares, with a nominal value of 1 penny per share ("Placing Shares") at a price of 175 pence per Placing Share (the "Placing Price") representing approximately 8.5 per cent. of Misys's existing issued share capital, with institutional investors (the "Placing"). The purpose of the Placing is to part finance the cash element of the transaction announced earlier today by Misys, whereby Misys will combine Misys Healthcare with Allscripts Healthcare Solutions Inc. and acquire a controlling stake of 54.5 per cent. in the combined entity (calculated on a fully diluted basis) (the "Transaction"). The Placing is expected to raise approximately £75 million in gross proceeds.

London, (13 February, 2008) – Misys plc (FTSE: MSY.L), the global applications software and services company, today announced the appointment of Carl Gibson as Director of Company Communications, effective immediately. He will be responsible for company communications and coordinating strategy and activities for the Misys group of companies.

Misys plc, the global application software and services company, today (24 January 2008) announces its interim results for the six months ended 30 November 2007.